Cumberland Pharmaceuticals Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products for hospital acute care, gastroenterology, oncology, and infectious diseases. Founded in 1999 and headquartered in Nashville, Tennessee, the company markets its portfolio primarily in the United States through dedicated hospital, field, and oncology sales divisions while establishing international partnerships for registration and distribution in markets including China, Saudi Arabia, Mexico, and Australia. Its core products include Acetadote (acetylcysteine injection) for acetaminophen poisoning; Caldolor (ibuprofen injection) for pain and fever, including in pediatric patients as young as three months and pre-operative use; Kristalose (lactulose oral solution), a prescription laxative for constipation; Sancuso (granisetron transdermal patch) for prevention of chemotherapy-induced nausea and vomiting; Vaprisol (conivaptan injection) for euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin injection) for serious bacterial infections such as hospital-acquired pneumonia and complicated skin infections. Recent developments include the October 2025 formation of Talicia Holdings Inc., a joint venture with RedHill Biopharma Ltd., where Cumberland invested $4 million for a 30% stake and assumed U.S. distribution responsibilities for Talicia (omeprazole, amoxicillin, rifabutin capsules), the FDA-approved all-in-one therapy for Helicobacter pylori infection; this arrangement enables Cumberland to record Talicia sales and share net revenues equally while leveraging its sales force for promotion. In the same month, Vibativ was added to a national group purchasing agreement with Premier Inc., enhancing access for over 4,350 U.S. hospitals and providers. Earlier in 2025, Cumberland reported positive Phase 2 FIGHT DMD trial results demonstrating improved heart function with ifetroban in Duchenne muscular dystrophy patients, alongside NMPA approval of Vibativ in China via partner SciClone Pharmaceuticals, regulatory approval of Caldolor in Mexico through PiSa Pharmaceuticals, and Vibativ launch in Saudi Arabia by Tabuk Pharmaceuticals; the company also posted 11.6% fourth-quarter 2024 revenue growth to $10.4 million.
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
Cumberland's Ifetroban Shows Potential to Limit Metastasis
Cumberland Expands Global Reach With Vibativ Launch in China
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex